

OBJECTIVES: Major depressive disorder affects approximately 10-15% of the population and is associated with significant morbidity and mortality. It is one of the leading causes of disability in young adults. A large proportion of the burden can be attributed to treatment-resistant depression (TRD). To understand the prevalence and disease burden of TRD in Western European countries, the US and Canada, a systematic literature search was performed. **METHODS:** OVID, the Cochrane Library and the CRD database were used to retrieve TRD publications in English language from January 2003-October 2013. In total, 6306 abstracts were identified. Predefined selection criteria regarding study design, patient population (age ≥ 12 years; US, Canada, Germany, Italy, France, Spain or UK; TRD defined as one treatment failure and high symptom severity e.g. MADRS ≥ 31 , or an inadequate response to ≥ 2 antidepressants) and outcomes of interest were applied. **RESULTS:** Only seven studies included prevalence and/or disease burden data. Five studies provided prevalence estimates which adhered to the strict TRD definition used for this review. Study design and definition of the patient population were critical in determining the prevalence rates, with the lowest rates found in US employer claims databases (11-15%), higher rates in commercial health insurance databases (29-31%) and the highest rates in a European multicenter study (51-56%). The database studies mainly included employed patients thereby likely underestimating the prevalence, whereas the European study likely overestimated the prevalence due to a less stringent TRD definition. Inconsistent data were reported regarding treatment outcomes, comorbidities, hospitalization and work productivity. There was no information on other outcomes such as health-related quality of life or functioning. **CONCLUSIONS:** No consistent data were found in the literature from January 2003-October 2013 regarding the epidemiology and disease burden of TRD. To determine the prevalence and disease burden for TRD, further studies are needed.

PMH15

PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA ACCORDING TO THE PRESENCE OR ABSENCE OF NEGATIVE SYMPTOMS

Sicras-Mainar A¹, Ruiz-Beato E², Mauriño J², Navarro-Artieda R³

¹Badalona Serveis Assistencials, Badalona, Barcelona, Spain, ²Roche Farma, S.A, Madrid, Spain,

³Hospital Universitari Germans Trias i Pujol, Badalona, Spain

OBJECTIVES: The aim of this study was to estimate the prevalence of metabolic syndrome (MS) in patients with schizophrenia according to the presence or absence of negative symptoms. **METHODS:** A retrospective, cohort study was conducted using electronic medical records from the health provider BSA (Badalona, Spain). All adult outpatients with a diagnosis of schizophrenia were followed for 12 months. Two study groups were defined by the presence or absence of negative symptoms based on the PANSS Marder Negative Symptoms Factor (N1-N4, N6, G7 and G16). MS prevalence was estimated using the NCEP ATP III criteria. Descriptive statistics and logistic regression models were applied. **RESULTS:** We studied 1,120 patients (mean age: 46.8 \pm 13.8 years; male: 58.4%). One or more negative symptoms were present in 52.5% of patients (95%CI: 49.6-55.4%). Dyslipidemia (48.7%), hypertension (38.2%), and diabetes mellitus (19.3%) were the most frequent comorbid conditions. Quetiapine, risperidone and olanzapine were the most common antipsychotic drugs administered. Patients with negative symptoms showed a greater mean number of comorbid conditions than patients without this symptomatology (8.5 and 7.0, respectively; $p < 0.001$). Prevalence of MS was 38.6% (CI: 35.7-41.5%), higher among patients with one or more negative symptoms (43.9% vs. 34.9%, respectively; $p = 0.002$). MS was associated with the presence of negative symptoms, age, and comorbidity (OR=1.6, 1.2, and 1.2, respectively; $p < 0.05$). **CONCLUSIONS:** Further studies are necessary to elucidate the association between the presence of negative symptoms and MS among patients with schizophrenia as well as the underlying mechanisms involved.

MENTAL HEALTH – Cost Studies

PMH16

THE POTENTIAL BENEFITS OF LONG-ACTING ATYPICAL ANTIPSYCHOTIC THERAPY IN PREVENTING RELAPSE IN BRAZIL

Tay-Teo K¹, Pezzullo L¹, Violin B², Dias T², Sardi P², Delatorre R², Pititto L³, Guarniero F³

¹Deloitte Access Economics, MELBOURNE, Australia, ²Monitor Deloitte, Sao Paulo, Brazil, ³Janssen Cilag, São Paulo, Brazil

OBJECTIVES: To quantify the economic burden of schizophrenia relapse in Brazil, and to estimate the impact of atypical Long Acting Injectables (LAIs) on relapse. **METHODS:** Administrative health service data from a Brazilian public system database (DATASUS) were used to estimate the number of relapse patients and related resource utilisation. Corresponding data for private system patients were estimated based on published literature and by extrapolating DATASUS data. A prevalence-based costing with a mixed bottom-up and top-down approach was used to quantify direct and indirect costs, disability adjusted life years (DALYS) and their associated monetary value. A decision-analytic model was constructed to evaluate the cost effectiveness of potentially transferring non-compliant patients from oral antipsychotics to atypical LAIs. All costs are presented in 2013 Brazilian real. **RESULTS:** In 2011-12, 88,721 patients with schizophrenia in Brazil experienced 263,037 episodes of relapse that resulted in hospital or outpatient care. The potential avoidable health care cost of relapse was R\$722.6 million. The estimated additional health care cost per DALY avoided was R\$5,049 if non-compliant patients could be transferred to atypical LAIs to achieve 5% overall utilisation. Reducing relapses would give Brazil potential avoidance of 1,335 DALYS, which corresponds to a saving of R\$482.8 million in the stock of health capital. **CONCLUSIONS:** The economic burden of schizophrenia relapse in Brazil is significant. Brazilian policymakers should provide greater access to LAIs.

PMH17

ANALYSIS OF 'REVOLVING DOOR' PATIENTS IN OPIOID DEPENDENT PATIENTS: THE IMPACT OF TREATMENT DISCONTINUATION ON RELAPSE RATES AND HEALTH CARE COSTS IN US PUBLIC HEALTH INSURANCE CLAIMS

Clay E¹, Zah V², Kharitonova E¹, Ruby J³, Abaléa S¹, Khemiri A⁴

¹Creativ-Ceutical, Paris, France, ²ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro,

³Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA, USA, ⁴Creativ-Ceutical, Tunis, Tunisia

OBJECTIVES: Buprenorphine/naloxone (BUP/NAL) combination is a well known treatment for opioid dependence. As a chronic relapsing disorder, some patients alternate between periods of on treatment and off treatment. The aim of this study was to compare health care resource utilization and costs between these patients and patients treated continuously. **METHODS:** Statistical analyses were conducted on a Medicaid insurance claims database (TruvenHealth MarketScan® Medicaid) from January 2007 to June 2012. Patients with at least two treatment episodes in the first year after the initial filled prescription were identified. The end of a treatment episode was defined as a period of 60 days with no filled BUP/NAL prescriptions following the theoretical end of the last filled prescription. An ordered logistic regression model was used to analyze the impact of initial treatment episode duration on the number of new episodes in the year following the end of the first episode. Health care resource utilization and related costs during the first year after initiation were compared between the two groups. **RESULTS:** 2,223 patients were included in the analysis. During the first year, 86% of patients had only one treatment episode, 13% had two and 1% had three. Compared to patients who remained in treatment continuously over 12 months, the multiple treatment episode group had lower medication costs (-\$2,877) but higher psychiatric inpatient costs (+\$720), non-psychiatric inpatient costs (+\$2001) and emergency room costs (+430) over 12 months. Total health care costs over 12 months were higher among multiple treatment episode patients (\$16,583 vs. \$15,123, $p = 0.0004$). **CONCLUSIONS:** Despite lower medication costs, total health care costs over 12 months were higher among patients with multiple treatment episodes compared to patients treated continuously.

PMH18

TREATMENT COST COMPARISON: PALIPERIDONE PALMITATE VERSUS RISPERIDONE LONG ACTING IN BRAZIL

Pititto L, Guarniero F, Antonio M

Janssen Cilag, São Paulo, Brazil

Janssen Cilag, São Paulo, Brazil

OBJECTIVES: To compare the treatment cost of paliperidone palmitate (PP) versus risperidone long acting (R-LA), both indicated for the treatment of schizophrenia in Brazil. **METHODS:** In Brazil, both (PP and R-LA) long acting 2nd generation antipsychotics are approved for the treatment of schizophrenia. Published literature shows no difference in safety and efficacy between them; therefore, a cost-minimization analysis was performed. Yearly treatment costs were calculated for an average dose of 37.5 mg per patient in the case of R-LA and 75 mg in the case of PP. The two initial treatment doses were considered: for PP, 150 mg on the 1st day and 100 mg on the 8th day, and for R-LA 21 days oral supplementation with 3 mg of risperidone, according to dosing intervals defined in the product label. Prices were gathered from the official price list (CMED – Apr'14). **RESULTS:** PP has the lowest cost of treatment, at R\$ 12,739 per patient in the 1st year – against R-LA R\$ 18,165 – and R\$ 11,359 in the 2nd year (R-LA has R\$ 17,971). Treatment with PP compared to R-LA may bring important savings to the payers (HMOs or Government), with potential to reduce the cost of treatment by 30% in the 1st year, and 37% in the 2nd year – allowing a higher number of patients to be treated at the same budget level. **CONCLUSIONS:** Although both molecules, PP and R-LA, have demonstrated similar efficacy, PP offers a cost reduction from the perspective of the Brazilian private health care system compared to R-LA. In addition, PP offers advantages that can have additional value for public and private payers alike such as a monthly injection and no need for cold chain. PP can therefore be considered a cost-saving therapeutic option for schizophrenia compared to R-LA.

PMH19

COSTS OF EMPLOYEES WITH TREATMENT-RESISTANT DEPRESSION BASED ON A CANADIAN PRIVATE CLAIMS DATABASE

Kellar J¹, Mittmann N², von Heymann C³, Zingaro J³, Kuriakose B⁴, Li A⁴

¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²Sunnybrook Health Sciences

Centre, Toronto, ON, Canada, ³Cubic Health Inc., Toronto, ON, Canada, ⁴Janssen Inc, Toronto,

ON, Canada

Approximately 10-20% of individuals with Major Depressive Disorder (MDD) fail to respond to antidepressant monotherapy. These individuals with treatment resistant depression (TRD) have been found to be frequent users of health care services, thus incurring significantly greater costs than those without TRD. **OBJECTIVES:** To investigate the cost of Treatment-Resistant Depression from a private payer perspective in Canada. **METHODS:** An employer-sponsored benefits plan database (2011/2012) was used to define a cohort of Non-TRD and TRD claimants. TRD claimants are defined as those on their third antidepressant monotherapy; or combination antidepressant therapy; or antidepressant augmented with lithium, thyroid hormone or an antipsychotic medication. The cost of prescription medication utilization, short-term disability (STD), and long-term disability (LTD) benefits for employees was calculated (2011 and 2012 \$CAN) for both Non-TRD and TRD groups. Descriptive statistics were used to characterize the cohort of claimants and employees, as well as resources and costs for employees. **RESULTS:** There were 55,324 and 61,028 employee claimants in 2011 and 2012, respectively. 717 (1.3%) and 798 (1.3%) were TRD claimants; 4,744 (8.6%) and 5,137 (8.4%) were Non-TRD claimants in 2011 and 2012, respectively. In 2011, the medication costs for treating depression was \$774 per TRD employee claimant compared to \$303 per Non-TRD claimant. STD costs were \$6,263 for TRD (n=79) and \$5,855 for Non-TRD (n=276). LTD costs were \$13,598 for TRD (n=80) and \$12,272 for Non-TRD (n=119). In 2012, the medication costs for treating depression per TRD employee claimant was \$794 compared to \$293 for Non-TRD claimants. STD costs were \$7,832 for TRD (n=86) and \$4,001 for Non-TRD (n=248). LTD costs were \$13,927 for TRD (n=89) and \$12,901 for Non-TRD (n=121). **CONCLUSIONS:** Claimants identified with TRD had higher medication, STD and LTD costs than those with Non-TRD. Limitations include lack of diagnostic information for claimants and small sample sizes for STD and LTD subgroups.